Shire Course Corrects Lifitegrast And Eyes Ophthalmology Prospects
This article was originally published in The Pink Sheet Daily
Executive Summary
The specialty pharma has worked with regulators to determine a next step for its late-stage eye drug and intends to build a business unit around the compound.